Drug
Tulmimetostat
Tulmimetostat: highest development phase Phase 1/2, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tulmimetostat NCT07190300 | Phase 1/2 | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
Latest
No recent events.
Follow Tulmimetostat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.